Media about us

• Russian investment vehicle sets sights on innovative drugs

  29 March 2013 Eugene Gerden, Chemistry World

  

  Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. Rusnano has been ploughing hundreds of millions of dollars into pioneering pharma companies with the aim of growing Russia’s domestic drug production, and making a tidy return by licensing drugs to foreign partners.

• Russia is becoming a player in global biopharma

  04 February 2013 Business New Europe (bne)

  

  A biotechnology revolution is gathering steam in Russia, spurred by state investment programs, a host of cross-border partnerships and a domestic market that international investors find highly attractive. The government is modernizing a decaying healthcare system by building new hospitals and introducing innovative technologies.

• Russia fund in consortium to back U.S. pharma firms

  20 December 2012 Megan Davies, Reuters

  

  Russian state technology firm Rusnano, alongside a group of investors, is investing $93 million in three U.S.-based pharmaceutical firms to develop drugs to treat illnesses such as epilepsy, the investors said on Wednesday.

• There is practically no venture financing institution in the field of Life Sciences in Russia

  07 August 2012 Kirill Sedov, Farmatsevticheskiy Vestnik

  

  In the interview to Farmatsevticheskiy Vestnik, Leonid Melamed, Team Drive Chairman of the Board of Directors said that the company having undertaken a venture project in the Russian pharmaceutical market had to act as a pioneer.

• Venture capital spurs Russian drug development – in California

  25 July 2012 Isabel Gorst, FT-Beyondbrics

  

  When the Kremlin invited a group of US venture capitalists to Russia during the financial crisis, some of the visitors saw as much an opportunity to scout for fresh sources of capital as they did a new place to invest in.

• Coda Therapeutics raise additional $20M for series B

  25 July 2012 Private Equity Hub

  CoDa Therapeutics has raised an additional $20 million from RusnanoMedInvest in a second close of its Series B financing round. This brings the total Series B Round to nearly $40 million following the first close late last year. All current investors, including Domain Associates, GBS Ventures and BioPacificVentures participated. San Diego-based CoDa is a biopharmaceutical company working to develop drug therapies for wounds that do not heal properly, including venous leg and diabetic foot ulcers.

• Russia’s Rusnano, Domain Invest $40 Million In San Diego’s CoDa

  24 July 2012 Ksenia Galouchko, Bloomberg

  

  Russian Nanotechnologies, the state- run technology holding, and Domain Associates, a U.S. venture fund, are investing about $40 million in San Diego-based biopharmaceutical company CoDa Therapeutics.

• RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects

  07 March 2012 Nanowerk News

  

  RUSNANO and Domain Associates, a U.S. venture capital firm specializing in leading-edge life sciences technologies, today announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.

• Rusnano, US fund to invest $760 mln in pharma venture

  06 March 2012 Megan Davies, Reuters

  

  Russian state technology firm Rusnano is teaming up with a U.S. venture fund to invest around $760 million in a number of U.S. healthcare and pharmaceuticals firms, establish a manufacturing facility in Russia and bring new drugs to the Russian market.

• Domain partners with RusNano on $760M biotech investment plan

  06 March 2012 John Carroll, Fierce Biotech

  

  The Russians are back. After capturing the attention of the nanobio crowd with a few hefty investments in the U.S., RusNano is now partnering with Domain Associates on a $760 million initiative that will invest in about 20 life sciences companies and construct a pharma manufacturing center in Russia to produce next-gen therapies.